Papp KA - Search Results

1

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B. Papp KA, et al. Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16. Br J Dermatol. 2017. PMID: 28600810

2

Etanercept in psoriasis.

Papp KA. Papp KA. Expert Opin Pharmacother. 2004 Oct;5(10):2139-46. doi: 10.1517/14656566.5.10.2139. Expert Opin Pharmacother. 2004. PMID: 15461549 Review.

3

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. Among authors: papp ka. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

4

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group. Papp KA, et al. Br J Dermatol. 2005 Jun;152(6):1304-12. doi: 10.1111/j.1365-2133.2005.06688.x. Br J Dermatol. 2005. PMID: 15948997 Clinical Trial.

5

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.

Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL; Efalizumab Study Group. Papp KA, et al. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S164-70. doi: 10.1016/j.jaad.2005.10.032. J Am Acad Dermatol. 2006. PMID: 16488338 Clinical Trial.

6

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Papp KA, et al. J Cutan Med Surg. 2005 Dec;9(6):313-23. doi: 10.1007/s10227-005-0117-0. J Cutan Med Surg. 2005. PMID: 16699903 Review.

7

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.

Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; Efalizumab Study Group. Papp KA, et al. Int J Dermatol. 2006 May;45(5):605-14. doi: 10.1111/j.1365-4632.2006.02777.x. Int J Dermatol. 2006. PMID: 16700803 Clinical Trial.

8

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. Dubertret L, et al. Among authors: papp ka. Br J Dermatol. 2006 Jul;155(1):170-81. doi: 10.1111/j.1365-2133.2006.07344.x. Br J Dermatol. 2006. PMID: 16792770 Clinical Trial.

9

Evaluation of efalizumab using safe psoriasis control.

Papp KA, Henninger E. Papp KA, et al. BMC Dermatol. 2006 Sep 19;6:8. doi: 10.1186/1471-5945-6-8. BMC Dermatol. 2006. PMID: 16984639 Free PMC article.

10

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.

Papp KA, Toth D, Rosoph L. Papp KA, et al. BMC Dermatol. 2006 Oct 26;6:9. doi: 10.1186/1471-5945-6-9. BMC Dermatol. 2006. PMID: 17067371 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

352 results

Search Page